Literature DB >> 2387630

Immunotherapeutic efficacy of bovine colostral immunoglobulins from a hyperimmunized cow against cryptosporidiosis in neonatal mice.

R Fayer1, A Guidry, B L Blagburn.   

Abstract

Infection with Cryptosporidium parvum, a ubiquitous protozoan parasite of virtually all mammals, can cause mild to severe diarrhea in immunocompetent hosts and life-threatening diarrhea in immunocompromised hosts. Passive immunotherapy of experimentally infected animals and naturally infected humans with hyperimmune bovine colostrum has been reported to be efficacious, whereas chemotherapy has not. In this study, the efficacy of specific immunoglobulin isotypes purified from bovine colostrum from a cow hyperimmunized with Cryptosporidium parvum was assessed in neonatal BALB/c mice. Mice were orally infected with oocysts and treated with whole whey immunoglobulin G1 (IgG1), IgG2, IgA, or IgM at six intervals from 22 to 66 h postinfection. In histologic sections of intestine examined at 72 h postinfection, the reduction in number of intestinal stages in treated mice versus untreated controls was very highly significant (P less than 0.0001). The greatest reduction in parasite number was found in mice treated with IgG1, IgA, or whey.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2387630      PMCID: PMC313595          DOI: 10.1128/iai.58.9.2962-2965.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Remission of diarrhoea due to cryptosporidiosis in an immunodeficient child treated with hyperimmune bovine colostrum.

Authors:  S Tzipori; D Roberton; C Chapman
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-15

2.  Library of monoclonal bovine immunoglobulins and monoclonal antibodies to bovine immunoglobulins.

Authors:  S Srikumaran; R A Goldsby; A J Guidry; B Hague; D V Onisk; P Srikumaran
Journal:  Hybridoma       Date:  1987-10

3.  Oral administration of bovine colostrum anti-cryptosporidia antibody fails to alter the course of human cryptosporidiosis.

Authors:  A Saxon; W Weinstein
Journal:  J Parasitol       Date:  1987-04       Impact factor: 1.276

4.  Chronic cryptosporidial diarrhoea and hyperimmune cow colostrum.

Authors:  S Tzipori; D Roberton; D A Cooper; L White
Journal:  Lancet       Date:  1987-08-08       Impact factor: 79.321

5.  Infection and diarrhea caused by Cryptosporidium sp. among Guatemalan infants.

Authors:  J R Cruz; F Cano; P Càceres; F Chew; G Pareja
Journal:  J Clin Microbiol       Date:  1988-01       Impact factor: 5.948

6.  Lacteal immunity to enteric cryptosporidiosis in mice: immune dams do not protect their suckling pups.

Authors:  H W Moon; D B Woodmansee; J A Harp; S Abel; B L Ungar
Journal:  Infect Immun       Date:  1988-03       Impact factor: 3.441

7.  Infectivity and neutralization of Cryptosporidium parvum sporozoites.

Authors:  M W Riggs; L E Perryman
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

8.  Cryptosporidiosis in children from some highland Costa Rican rural and urban areas.

Authors:  L Mata; H Bolaños; D Pizarro; M Vives
Journal:  Am J Trop Med Hyg       Date:  1984-01       Impact factor: 2.345

9.  Antigens of Cryptosporidium sporozoites recognized by immune sera of infected animals and humans.

Authors:  J R Mead; M J Arrowood; C R Sterling
Journal:  J Parasitol       Date:  1988-02       Impact factor: 1.276

10.  Cryptosporidiosis in Haitian children.

Authors:  J W Pape; E Levine; M E Beaulieu; F Marshall; R Verdier; W D Johnson
Journal:  Am J Trop Med Hyg       Date:  1987-03       Impact factor: 2.345

View more
  25 in total

Review 1.  Passive immunity against human pathogens using bovine antibodies.

Authors:  C Weiner; Q Pan; M Hurtig; T Borén; E Bostwick; L Hammarström
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

2.  Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate.

Authors:  D M Lyerly; E F Bostwick; S B Binion; T D Wilkins
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

3.  Quantification of in vitro and in vivo Cryptosporidium parvum infection by using real-time PCR.

Authors:  Nihal T Godiwala; Alain Vandewalle; Honorine D Ward; Brett A Leav
Journal:  Appl Environ Microbiol       Date:  2006-06       Impact factor: 4.792

4.  Monoclonal antibody immunotherapy in nude mice persistently infected with Cryptosporidium parvum.

Authors:  J M Bjorneby; B D Hunsaker; M W Riggs; L E Perryman
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

5.  Enteral human serum immunoglobulin treatment of cryptosporidiosis in mice with severe combined immunodeficiency.

Authors:  T L Kuhls; S L Orlicek; D A Mosier; D L Crawford; V L Abrams; R A Greenfield
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

6.  Obtaining hyperimmune anti-Cryptosporidium parvum ovine colostrum. A study of the humoral immune response in immunized sheep.

Authors:  S Martín-Gómez; M A Alvarez-Sánchez; F A Rojo-Vázquez
Journal:  Parasitol Res       Date:  2005-11-16       Impact factor: 2.289

7.  Cloning and expression of a cDNA encoding epitopes shared by 15- and 60-kilodalton proteins of Cryptosporidium parvum sporozoites.

Authors:  M C Jenkins; R Fayer; M Tilley; S J Upton
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

8.  The gamma interferon gene knockout mouse: a highly sensitive model for evaluation of therapeutic agents against Cryptosporidium parvum.

Authors:  J K Griffiths; C Theodos; M Paris; S Tzipori
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

9.  Anti-Cryptosporidium parvum antibodies inhibit infectivity in vitro and in vivo.

Authors:  P S Doyle; J Crabb; C Petersen
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

10.  Microbial adhesion of Cryptosporidium parvum: identification of a colostrum-derived inhibitory lipid.

Authors:  Joann Schmidt; Mark S Kuhlenschmidt
Journal:  Mol Biochem Parasitol       Date:  2008-07-15       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.